New insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 17, Issue 10, 2011, Pages 2192-2204

  Shores, Darla R ^a   Binion, David G ^b   Freeman, Bruce A ^c   Baker, Paul R S ^c  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

fatty acids; inflammation; inflammatory bowel disease; metabolism; therapy

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CD59 ANTIGEN; CERAMIDE; CHOLESTEROL; DOCOSAHEXAENOIC ACID; ELECTROPHILE; FATTY ACID; FATTY ACID TRANSPORTER; HIGH DENSITY LIPOPROTEIN; ICOSANOID; ICOSATETRAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; LINOLEIC ACID; LIPOPROTEIN; LIPOXIN; LIPOXYGENASE; MITOGEN ACTIVATED PROTEIN KINASE; OLEIC ACID; OMEGA 3 FATTY ACID; PHOSPHOLIPID; PROSTAGLANDIN SYNTHASE; SHORT CHAIN FATTY ACID; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTING CELL; CARBOHYDRATE INTAKE; CELL LEVEL; CHOLESTEROL METABOLISM; CROHN DISEASE; CYTOKINE RELEASE; DENDRITIC CELL; DIETARY INTAKE; ENTERIC FEEDING; ENTERITIS; ENVIRONMENTAL FACTOR; GENE EXPRESSION; GENETIC RISK; HELPER CELL; HUMAN; HYDROXYLATION; HYPOCHOLESTEROLEMIA; INTESTINE EPITHELIUM CELL; INTESTINE FLORA; INTESTINE INFECTION; INTESTINE MUCOSA; LIPID DIET; LIPID METABOLISM; LIPID OXIDATION; LIPOPROTEIN METABOLISM; MEDIATOR RELEASE; MUCOSAL IMMUNITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INDUCTION; REVIEW; T LYMPHOCYTE ACTIVATION; TH17 CELL; TH2 CELL; TISSUE LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; ULCERATIVE COLITIS;

FATTY ACIDS; HUMANS; INFLAMMATORY BOWEL DISEASES; LIPID METABOLISM; SIGNAL TRANSDUCTION;

EID: 80052729447     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21560     Document Type: Review

References (135)

1. Abraham C, Cho JH., Inflammatory bowel disease. N Engl J Med. 2009; 361: 2066-2078.
2. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, et al. The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol. 2010; 105: 289-297.
3. Marrero F, Qadeer MA, Lashner BA., Severe complications of inflammatory bowel disease. Med Clin North Am. 2008; 92: 671-686. ix.
4. Kaser A, Zeissig S, Blumberg RS., Inflammatory bowel disease. Annu Rev Immunol. 2010; 28: 573-621.
5. Shih DQ, Targan SR, McGovern D,. Recent advances in IBD pathogenesis: genetics and immunobiology. Curr Gastroenterol Rep. 2008; 10: 568-575.
6. Weisburger JH., Dietary fat and risk of chronic disease: mechanistic insights from experimental studies. J Am Diet Assoc. 1997; 97: S16-23.
7. Huibregtse IL, van Lent AU, van Deventer SJ., Immunopathogenesis of IBD: insufficient suppressor function in the gut? Gut. 2007; 56: 584-592.
8. Abraham C, Cho J., Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15: 1090-1100.
9. Wolowczuk I, Verwaerde C, Viltart O, et al. Feeding our immune system: impact on metabolism. Clin Dev Immunol. 2008; 2008: 639803.
10. Leslie CC., Regulation of arachidonic acid availability for eicosanoid production. Biochem Cell Biol. 2004; 82: 1-17.
11. Cathcart MK., Signal-activated phospholipase regulation of leukocyte chemotaxis. J Lipid Res. 2009; 50 (suppl): S231-236.
12. Calder, PC., Dietary modification of inflammation with lipids. Proc Nutr Soc. 2002; 61: 345-358.
13. Ferrer R, Moreno JJ., Role of eicosanoids on intestinal epithelial homeostasis. Biochem Pharmacol. 2010; 80: 431-438.
14. Zmijewski JW, Landar A, Watanabe N, et al. Cell signalling by oxidized lipids and the role of reactive oxygen species in the endothelium. Biochem Soc Trans. 2005; 33: 1385-1389.
15. Gayarre J, Sanchez D, Sanchez-Gomez FJ, et al. Addition of electrophilic lipids to actin alters filament structure. Biochem Biophys Res Commun. 2006; 349: 1387-1393.
16. Sanchez-Gomez FJ, Gayarre J, Avellano MI, et al. Direct evidence for the covalent modification of glutathione-S-transferase P1-1 by electrophilic prostaglandins: implications for enzyme inactivation and cell survival. Arch Biochem Biophys. 2007; 457: 150-159.
17. Levonen AL, Landar A, Ramachandran A, et al. Cellular mechanisms of redox cell signalling: role of cysteine modification in controlling antioxidant defences in response to electrophilic lipid oxidation products. Biochem J. 2004; 378: 373-382.
18. Shibata T, Yamada T, Ishii T, et al. Thioredoxin as a molecular target of cyclopentenone prostaglandins. J Biol Chem. 2003; 278: 26046-26054.
19. Yu X, Egner PA, Wakabayashi J, et al. Nrf2-mediated induction of cytoprotective enzymes by 15-deoxy-Delta12,14-prostaglandin J2 is attenuated by alkenal/one oxidoreductase. J Biol Chem. 2006; 281: 26245-26252.
20. Crabb JW, O'Neil J, Miyagi M, et al. Hydroxynonenal inactivates cathepsin B by forming Michael adducts with active site residues. Protein Sci. 2002; 11: 831-840.
21. Uchida K, Stadtman ER., Modification of histidine residues in proteins by reaction with 4-hydroxynonenal. Proc Natl Acad Sci U S A. 1992; 89: 4544-4548.
22. Ishii T, Tatsuda E, Kumazawa S, et al. Molecular basis of enzyme inactivation by an endogenous electrophile 4-hydroxy-2-nonenal: identification of modification sites in glyceraldehyde-3-phosphate dehydrogenase. Biochemistry. 2003; 42: 3474-3480.
23. Uchida K, Stadtman ER., Covalent attachment of 4-hydroxynonenal to glyceraldehyde-3-phosphate dehydrogenase. A possible involvement of intra- and intermolecular cross-linking reaction. J Biol Chem. 1993; 268: 6388-6393.
24. Holtzclaw WD, Dinkova-Kostova AT, Talalay P., Protection against electrophile and oxidative stress by induction of phase 2 genes: the quest for the elusive sensor that responds to inducers. Adv Enzyme Regul. 2004; 44: 335-367.
25. Liebler DC., Protein damage by reactive electrophiles: targets and consequences. Chem Res Toxicol. 2008; 21: 117-128.
26. Tjonneland A, Overvad K, Bergmann MM, et al. Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of ulcerative colitis: a nested case-control study within a European prospective cohort study. Gut. 2009; 58: 1606-1611.
27. Alzoghaibi MA, Walsh SW, Willey A, et al. Linoleic acid, but not oleic acid, upregulates the production of interleukin-8 by human intestinal smooth muscle cells isolated from patients with Crohn's disease. Clin Nutr. 2003; 22: 529-535.
28. Ramakers JD, Mensink RP, Verstege MI, et al. An arachidonic acid-enriched diet does not result in more colonic inflammation as compared with fish oil- or oleic acid-enriched diets in mice with experimental colitis. Br J Nutr. 2008; 100: 347-354.
29. Fernandez-Banares F, Esteve-Comas M, Mane J, et al. Changes in mucosal fatty acid profile in inflammatory bowel disease and in experimental colitis: a common response to bowel inflammation. Clin Nutr. 1997; 16: 177-183.
30. Buhner S, Nagel E, Korber J, et al. Ileal and colonic fatty acid profiles in patients with active Crohn's disease. Gut. 1994; 35: 1424-1428.
31. Pacheco S, Hillier K, Smith C., Increased arachidonic acid levels in phospholipids of human colonic mucosa in inflammatory bowel disease. Clin Sci (Lond). 1987; 73: 361-364.
32. Nishida T, Miwa H, Shigematsu A, et al. Increased arachidonic acid composition of phospholipids in colonic mucosa from patients with active ulcerative colitis. Gut. 1987; 28: 1002-1007.
33. Nieto N, Giron MD, Suarez MD, et al. Changes in plasma and colonic mucosa fatty acid profiles in rats with ulcerative colitis induced by trinitrobenzene sulfonic acid. Dig Dis Sci. 2009; 1998; 43: 2688-2695.
34. Harvey KA, Walker CL, Pavlina TM, et al. Long-chain saturated fatty acids induce pro-inflammatory responses and impact endothelial cell growth. Clin Nutr. 2010; 29: 492-500.
35. Esteve-Comas M, Nunez MC, Fernandez-Banares F, et al. Abnormal plasma polyunsaturated fatty acid pattern in non-active inflammatory bowel disease. Gut. 1993; 34: 1370-1373.
36. Esteve-Comas M, Ramirez M, Fernandez-Banares F, et al. Plasma polyunsaturated fatty acid pattern in active inflammatory bowel disease. Gut. 1992; 33: 1365-1369.
37. Ueda Y, Kawakami Y, Kunii D, et al. Elevated concentrations of linoleic acid in erythrocyte membrane phospholipids in patients with inflammatory bowel disease. Nutr Res. 2008; 28: 239-244.
38. Morita H, Nakanishi K, Dohi T, et al. Phospholipid turnover in the inflamed intestinal mucosa: arachidonic acid-rich phosphatidyl/plasmenyl- ethanolamine in the mucosa in inflammatory bowel disease. J Gastroenterol. 1999; 34: 46-53.
39. Jupp J, Hillier K, Elliott DH, et al. Colonic expression of leukotriene-pathway enzymes in inflammatory bowel diseases. Inflamm Bowel Dis. 2007; 13: 537-546.
40. Sharon P, Stenson WF., Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology. 1984; 86: 453-460.
41. Nielsen OH, Ahnfelt-Ronne I, Elmgreen J., Abnormal metabolism of arachidonic acid in chronic inflammatory bowel disease: enhanced release of leucotriene B4 from activated neutrophils. Gut. 1987; 28: 181-185.
42. Wiercinska-Drapalo A, Flisiak R, Prokopowicz D., Mucosal and plasma prostaglandin E2 in ulcerative colitis. Hepatogastroenterology. 1999; 46: 2338-2342.
43. Sasaki S, Hirata I, Maemura K, et al. Prostaglandin E2 inhibits lesion formation in dextran sodium sulphate-induced colitis in rats and reduces the levels of mucosal inflammatory cytokines. Scand J Immunol. 2000; 51: 23-28.
44. Heimerl S, Moehle C, Zahn A, et al. Alterations in intestinal fatty acid metabolism in inflammatory bowel disease. Biochim Biophys Acta. 2006; 1762: 341-350.
45. Schwenk RW, Holloway GP, Luiken JJ, et al. Fatty acid transport across the cell membrane: regulation by fatty acid transporters. Prostaglandins Leukot Essent Fatty Acids. 2010; 82: 149-152.
46. Wiercinska-Drapalo A, Jaroszewicz J, Siwak E, et al. Intestinal fatty acid binding protein (I-FABP) as a possible biomarker of ileitis in patients with ulcerative colitis. Regul Pept. 2008; 147: 25-28.
47. Reiff C, Delday M, Rucklidge G, et al. Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 2009; 15: 1721-1736.
48. Lichtenberger LM., The hydrophobic barrier properties of gastrointestinal mucus. Annu Rev Physiol. 1995; 57: 565-583.
49. Podolsky DK., Inflammatory bowel disease. N Engl J Med. 2002; 347: 417-429.
50. Ehehalt R, Wagenblast J, Erben G, et al. Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoElectrospray-tandem mass spectrometry. Scand J Gastroenterol. 2004; 39: 737-742.
51. Sawai T, Drongowski RA, Lampman RW, et al. The effect of phospholipids and fatty acids on tight-junction permeability and bacterial translocation. Pediatr Surg Int. 2001; 17: 269-274.
52. Fabia R, Ar'Rajab A, Willen R, et al. Effects of phosphatidylcholine and phosphatidylinositol on acetic-acid-induced colitis in the rat. Digestion. 1992; 53: 35-44.
53. Mourelle M, Guarner F, Malagelada JR., Polyunsaturated phosphatidylcholine prevents stricture formation in a rat model of colitis. Gastroenterology. 1996; 110: 1093-1097.
54. Podolsky DK, Isselbacher KJ., Composition of human colonic mucin. Selective alteration in inflammatory bowel disease. J Clin Invest. 1983; 72: 142-153.
55. Podolsky DK, Isselbacher KJ., Glycoprotein composition of colonic mucosa. Specific alterations in ulcerative colitis. Gastroenterology. 1984; 87: 991-998.
56. Ballou LR, Laulederkind SJ, Rosloniec EF, et al. Ceramide signalling and the immune response. Biochim Biophys Acta. 1996; 1301: 273-287.
57. Bauer J, Liebisch G, Hofmann C, et al. Lipid alterations in experimental murine colitis: role of ceramide and imipramine for matrix metalloproteinase-1 expression. PLoS One. 2009; 4: e7197.
58. Sengupta N, MacDonald TT., The role of matrix metalloproteinases in stromal/epithelial interactions in the gut. Physiology (Bethesda). 2007; 22: 401-409.
59. Ravi A, Garg P, Sitaraman SV., Matrix metalloproteinases in inflammatory bowel disease: boon or a bane ? Inflamm Bowel Dis. 2007; 13: 97-107.
60. Meijer MJ, Mieremet-Ooms MA, van der Zon AM, et al. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig Liver Dis. 2007; 39: 733-739.
61. Meijer MJ, Mieremet-Ooms MA, van Hogezand RA, et al. Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease. World J Gastroenterol. 2007; 13: 2960-2966.
62. Pedersen G, Saermark T, Kirkegaard T, et al. Spontaneous and cytokine induced expression and activity of matrix metalloproteinases in human colonic epithelium. Clin Exp Immunol. 2009; 155: 257-265.
63. Hrabovsky V, Zadak Z, Blaha V, et al. Cholesterol metabolism in active Crohn's disease. Wien Klin Wochenschr. 2009; 121: 270-275.
64. Chiarla C, Giovannini I, Giuliante F, et al. Severe hypocholesterolemia in surgical patients, sepsis, and critical illness. J Crit Care. 2010; 25: 361. e7-361. e12.
65. Levy E, Rizwan Y, Thibault L, et al. Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. Am J Clin Nutr. 2000; 71: 807-815.
66. Ripolles Piquer B, Nazih H, Bourreille A, et al. Altered lipid, apolipoprotein, and lipoprotein profiles in inflammatory bowel disease: consequences on the cholesterol efflux capacity of serum using Fu5AH cell system. Metabolism. 2006; 55: 980-988.
67. Malle E, Steinmetz A, Raynes JG., Serum amyloid A (SAA): an acute phase protein and apolipoprotein. Atherosclerosis. 1993; 102: 131-146.
68. Jousilahti P, Salomaa V, Rasi V, et al. The association of c-reactive protein, serum amyloid a and fibrinogen with prevalent coronary heart disease-baseline findings of the PAIS project. Atherosclerosis. 2001; 156: 451-456.
69. Dagli N, Poyrazoglu OK, Dagli AF, et al. Is inflammatory bowel disease a risk factor for early atherosclerosis? Angiology. 2010; 61: 198-204.
70. Hillier K, Jewell R, Dorrell L, et al. Incorporation of fatty acids from fish oil and olive oil into colonic mucosal lipids and effects upon eicosanoid synthesis in inflammatory bowel disease. Gut. 1991; 32: 1151-1155.
71. Calder PC., Polyunsaturated fatty acids, inflammatory processes and inflammatory bowel diseases. Mol Nutr Food Res. 2008; 52: 885-897.
72. Belluzzi A., Polyunsaturated fatty acids (n-3 PUFAs) and inflammatory bowel disease (IBD): pathogenesis and treatment. Eur Rev Med Pharmacol Sci. 2004; 8: 225-229.
73. Feagan BG, Sandborn WJ, Mittmann U, et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA. 2008; 299: 1690-1697.
74. MacLean CH, Mojica WA, Newberry SJ, et al. Systematic review of the effects of n-3 fatty acids in inflammatory bowel disease. Am J Clin Nutr. 2005; 82: 611-619.
75. Turner D, Zlotkin SH, Shah PS, et al. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009:CD006320.
76. Turner D, Steinhart AH, Griffiths AM,. Omega 3 fatty acids (fish oil) for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007:CD006443.
77. Oh da Y, Talukdar S, Bae EJ, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell. 2010; 142: 687-698.
78. Akobeng AK, Thomas AG,. Enteral nutrition for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2007:CD005984.
79. Smith PA., Nutritional therapy for active Crohn's disease. World J Gastroenterol. 2008; 14: 4420-4423.
80. Bamba T, Shimoyama T, Sasaki M, et al. Dietary fat attenuates the benefits of an elemental diet in active Crohn's disease: a randomized, controlled trial. Eur J Gastroenterol Hepatol. 2003; 15: 151-157.
81. Gassull MA, Fernandez-Banares F, Cabre E, et al. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease: results of a double blind randomised multicentre European trial. Gut. 2002; 51: 164-168.
82. Leiper K, Woolner J, Mullan MM, et al. A randomised controlled trial of high versus low long chain triglyceride whole protein feed in active Crohn's disease. Gut. 2001; 49: 790-794.
83. Hamer HM, Jonkers D, Venema K, et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther. 2008; 27: 104-119.
84. Kles KA, Chang EB., Short-chain fatty acids impact on intestinal adaptation, inflammation, carcinoma, and failure. Gastroenterology. 2006; 130: S100-105.
85. Sturm A, Dignass AU., Epithelial restitution and wound healing in inflammatory bowel disease. World J Gastroenterol. 2008; 14: 348-353.
86. Treem WR, Ahsan N, Shoup M, et al. Fecal short-chain fatty acids in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 1994; 18: 159-164.
87. Weylandt KH, Kang JX, Wiedenmann B, et al. Lipoxins and resolvins in inflammatory bowel disease. Inflamm Bowel Dis. 2007; 13: 797-799.
88. Serhan CN., Systems approach to inflammation resolution: identification of novel anti-inflammatory and pro-resolving mediators. J Thromb Haemost. 2009; 7 (suppl 1): 44-48.
89. Goh J, Godson C, Brady HR, et al. Lipoxins: pro-resolution lipid mediators in intestinal inflammation. Gastroenterology. 2003; 124: 1043-1054.
90. Mangino MJ, Brounts L, Harms B, et al. Lipoxin biosynthesis in inflammatory bowel disease. Prostaglandins Other Lipid Mediat. 2006; 79: 84-92.
91. Levy BD., Resolvins and protectins: natural pharmacophores for resolution biology. Prostaglandins Leukot Essent Fatty Acids. 2010; 82: 327-332.
92. Arita M, Yoshida, M, Hong S, et al. Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A. 2005; 102: 7671-7676.
93. Ishida T, Yoshida M, Arita M, et al. Resolvin E1, an endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate sodium-induced colitis. Inflamm Bowel Dis. 2010; 16: 87-95.
94. Campbell EL, MacManus CF, Kominsky DJ, et al. Resolvin E1-induced intestinal alkaline phosphatase promotes resolution of inflammation through LPS detoxification. Proc Natl Acad Sci U S A. 2010; 107: 14298-14303.
95. Groeger A, Cipollina C, Cole M, et al. Cyclooxygenase-2 generates anti-inflammatory mediators from omega-3 fatty acids. Nat Chem Biol. 2010; 6: 433-441.
96. Baker PR, Schopfer FJ, Sweeney S, et al. Red cell membrane and plasma linoleic acid nitration products: synthesis, clinical identification, and quantitation. Proc Natl Acad Sci U S A. 2004; 101: 11577-11582.
97. Baker PRS, Lin Y, Schopfer FJ, et al. Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous PPAR ligands. J Biol Chem. 2005; 280: 42464-42475.
98. Baker PR, Schopfer FJ, O'Donnell VB, et al. Convergence of nitric oxide and lipid signaling: anti-inflammatory nitro-fatty acids. Free Radic Biol Med. 2009; 46: 989-1003.
99. Napolitano A, Camera E, Picardo M, et al. Acid-promoted reactions of ethyl linoleate with nitrite ions: formation and structural characterization of isomeric nitroalkene, nitrohydroxy, and novel 3-nitro-1,5-hexadiene and 1,5-dinitro-1, 3-pentadiene products. J.Org.Chem. 2000; 65: 4853-4860.
100. Napolitano A, Crescenzi O, Camera E, et al. The acid-promoted reaction of ethyl linoleate with nitrite. New insights from 15N-labeling and peculier reactivity of a model skipped diene. Tetrahedron. 2004; 58: 5061-5067.
101. Nadtochiy SM, Baker PRS, Freeman BA, et al. Nitration of linoleic acid in mitochondria during ischemic preconditioning: cardioprotection via activation of mitochondrial H+ leak. Cardiovasc Res. 2008 [Epub ahead of print].
102. Coles B, Bloodsworth A, Clark SR, et al. Nitrolinoleate inhibits superoxide generation, degranulation, and integrin expression by human neutrophils: novel antiinflammatory properties of nitric oxide-derived reactive species in vascular cells. Circ Res. 2002; 91: 375-381.
103. Coles B, Bloodsworth A, Eiserich JP, et al. Nitrolinoleate inhibits platelet activation by attenuating calcium mobilization and inducing phosphorylation of vasodilator-stimulated phosphoprotein through elevation of cAMP. J Biol Chem. 2002; 277: 5832-5840.
104. Wright MM, Schopfer FJ, Baker PR, et al. Fatty acid transduction of nitric oxide signaling: nitrolinoleic acid potently activates endothelial heme oxygenase 1 expression. Proc Natl Acad Sci U S A. 2006; 103: 4299-4304.
105. Li Y, Zhang J, Schopfer FJ, et al. Molecular recognition of nitrated fatty acids by PPAR gamma. Nat Struct Mol Biol. 2008; 15: 865-867.
106. Schopfer FJ, Lin Y, Baker PR, et al. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc Natl Acad Sci U S A. 2005; 102: 2340-2345.
107. Baker LM, Baker PR, Golin-Bisello F, et al. Nitro-fatty acid reaction with glutathione and cysteine. Kinetic analysis of thiol alkylation by a Michael addition reaction. J Biol Chem. 2007; 282: 31085-31093.
108. Batthyany C, Schopfer FJ, Baker PR, et al. Reversible post-translational modification of proteins by nitrated fatty acids in vivo. J Biol Chem. 2006; 281: 20450-20463.
109. Cui T, Schopfer FJ, Zhang J, et al. Nitrated fatty acids: Endogenous anti-inflammatory signaling mediators. J Biol Chem. 2006; 281: 35686-35698.
110. Borniquel S, Jansson EA, Cole MP, et al. Nitrated oleic acid up-regulates PPARgamma and attenuates experimental inflammatory bowel disease. Free Radic Biol Med. 2010; 48: 499-505.
111. Varga T, Nagy L., Nuclear receptors, transcription factors linking lipid metabolism and immunity: the case of peroxisome proliferator-activated receptor gamma. Eur J Clin Invest. 2008; 38: 695-707.
112. Dubuquoy L, Rousseaux C, Thuru X, et al. PPARgamma as a new therapeutic target in inflammatory bowel diseases. Gut. 2006; 55: 1341-1349.
113. Dubuquoy L, Jansson EA, Deeb S, et al. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology. 2003; 124: 1265-1276.
114. Adachi M, Kurotani R, Morimura K, et al. Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut. 2006; 55: 1104-1113.
115. Nakajima A, Wada K, Miki H, et al. Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfusion injury. Gastroenterology. 2001; 120: 460-469.
116. Chen Q, Chen J, Sun T, et al. A yeast two-hybrid technology-based system for the discovery of PPARgamma agonist and antagonist. Anal Biochem. 2004; 335: 253-259.
117. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator- activated receptor-gamma. J Exp Med. 2005; 201: 1205-1215.
118. Stolfi C, Pellegrini R, Franze E, et al. Molecular basis of the potential of mesalazine to prevent colorectal cancer. World J Gastroenterol. 2008; 14: 4434-4439.
119. Lewis JD, Lichtenstein GR, Deren JJ, et al. Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Gastroenterology. 2008; 134: 688-695.
120. Elbrecht A, Chen Y, Adams A, et al. L-764406 is a Partial agonist of human peroxisome proliferator-activated receptor gamma. The role of Cys313 in ligand binding. J Biol Chem. 1999; 274: 7913-7922.
121. Leesnitzer LM, Parks DJ, Bledsoe RK, et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry. 2002; 41: 6640-6650.
122. Schopfer FJ, Cole MP, Groeger AL, et al. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions. J Biol Chem. 2010; 285: 12321-12333.
123. Schopfer FJ, Lin Y, Baker PR, et al. Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc Natl Acad Sci U S A. 2005; 102: 2340-2345.
124. Groeger AL, Cipollina C, Cole MP, et al. Cyclooxygenase-2 generates anti-inflammatory mediators from omega-3 fatty acids. Nat Chem Biol. 2010; 6: 433-441.
125. Marion-Letellier R, Dechelotte P, Iacucci M, et al. Dietary modulation of peroxisome proliferator-activated receptor gamma. Gut. 2009; 58: 586-593.
126. Reynolds CM, Roche HM., Conjugated linoleic acid and inflammatory cell signalling. Prostaglandins Leukot Essent Fatty Acids. 2010; 82: 199-204.
127. Reynolds CM, Loscher CE, Moloney AP, et al. Cis-9, trans-11-conjugated linoleic acid but not its precursor trans-vaccenic acid attenuate inflammatory markers in the human colonic epithelial cell line Caco-2. Br J Nutr. 2008; 100: 13-17.
128. Loscher CE, Draper E, Leavy O, et al. Conjugated linoleic acid suppresses NF-kappa B activation and IL-12 production in dendritic cells through ERK-mediated IL-10 induction. J Immunol. 2005; 175: 4990-4998.
129. Zhao L, Yin J, Li D, et al. Conjugated linoleic acid can prevent tumor necrosis factor gene expression by inhibiting nuclear factor binding activity in peripheral blood mononuclear cells from weaned pigs challenged with lipopolysaccharide. Arch Anim Nutr. 2005; 59: 429-438.
130. Changhua L, Jindong Y, Defa L, et al. Conjugated linoleic acid attenuates the production and gene expression of proinflammatory cytokines in weaned pigs challenged with lipopolysaccharide. J Nutr. 2005; 135: 239-244.
131. Reynolds CM, Draper E, Keogh B, et al. A conjugated linoleic acid-enriched beef diet attenuates lipopolysaccharide-induced inflammation in mice in part through PPARgamma-mediated suppression of toll-like receptor 4. J Nutr. 2009; 139: 2351-2357.
132. Marion-Letellier R, Butler M, Dechelotte P, et al. Comparison of cytokine modulation by natural peroxisome proliferator-activated receptor gamma ligands with synthetic ligands in intestinal-like Caco-2 cells and human dendritic cells-potential for dietary modulation of peroxisome proliferator-activated receptor gamma in intestinal inflammation. Am J Clin Nutr. 2008; 87: 939-948.
133. Bassaganya-Riera J, Hontecillas R., Dietary conjugated linoleic acid and n-3 polyunsaturated fatty acids in inflammatory bowel disease. Curr Opin Clin Nutr Metab Care. 2010; 13: 569-573.
134. Bassaganya-Riera J, Reynolds K, Martino-Catt S, et al. Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology. 2004; 127: 777-791.
135. Evans NP, Misyak SA, Schmelz EM, et al. Conjugated linoleic acid ameliorates inflammation-induced colorectal cancer in mice through activation of PPARgamma. J Nutr. 2010; 140: 515-521.